Macter International Limited (PSX: MACTER) has launched Semaglutide in Pakistan in Pre-Filled Syringe (PFS) and Pre-Filled ...
Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook ...
Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...
Everyday Health on MSN
Walmart to Offer Discounted GLP-1 Drugs, Following Costco, Sam’s Club, and CVS
Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, Ozempic, or Wegovy.
Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...
Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will ...
People are trying mini doses of GLP-1 drugs to lose weight or maintain weight loss, but doctors urge caution, calling the ...
Demand for popular weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) has long outpaced supply, forcing many patients with obesity to visit compounding pharmacies to get ...
Zacks.com on MSN
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...
The stock fell as much as 17.13 per cent during the session to hit an intraday low of Rs 2,116.30, before recovering some ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback